Filing identity and period
Important identity mismatch: The supplied filing is Anzu Special Acquisition Corp I’s Form 10-Q for the quarter ended September 30, 2022—not a filing by Envoy Medical, Inc. The summary below reflects the filing actually provided.
Anzu was a blank-check company seeking a business combination, with a stated focus on businesses using transformative technologies for industrial applications. It had not commenced operations or generated operating revenue; activity related to its target search and public-company costs.
Financial results and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Operating expenses | $1.03 million | $2.99 million | $3.42 million | $4.24 million |
| Net income | $5.69 million | $5.57 million | $21.24 million | $4.47 million |
| Net income per share, basic and diluted | $0.11 | $0.10 | $0.40 | $0.10 |
| Net cash used in operating activities | Not provided by quarter | $1.81 million | $2.36 million |
- Q3 and nine-month net income was driven substantially by non-operating items, including gains from the decrease in warrant liabilities and forgiveness of deferred underwriting fees. Nine-month 2022 results also included $2.53 million of trust-account interest.
- At September 30, 2022, cash was $301,997, trust-account investments were $427.11 million, and total liabilities were $18.28 million. Class A shares subject to redemption were recorded at $426.88 million.
- Working-capital deficit was $5.41 million, compared with $1.82 million at December 31, 2021. A $1.50 million interest-free working-capital loan from the sponsor was outstanding. There was no long-term debt reported.
- Warrant liabilities fell to $1.87 million from $21.06 million at year-end 2021; the resulting fair-value gain materially boosted reported earnings. The deferred underwriting-fee liability was reduced by $4.46 million after certain underwriters waived their fees.
- The cash-flow statement reported $1.81 million of operating cash use and $1.50 million of financing inflows from the sponsor loan for the first nine months of 2022.
Material changes, outlook and risks
- Operating expenses declined versus the comparable periods, while reported net income increased year to date, primarily because of warrant-liability remeasurement, trust interest and the underwriting-fee waiver—not operating revenue.
- The company said it had reviewed potential targets but could not determine whether it would complete a combination with any reviewed or other target. No specific transaction or financial guidance is provided in the supplied filing text.
- The company had until March 4, 2023, unless shareholders approved an extension, to complete a business combination. If it failed, it was required to wind up and redeem public shares; warrants could expire worthless.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern if it did not complete a business combination. Available working capital was limited, and sponsor or third-party financing beyond stated commitments was not assured.
- The filing identifies possible effects from COVID-19 and the war in Ukraine as uncertain. It also warns that the federal 1% excise tax on certain stock repurchases after December 31, 2022 could reduce funds available for redemptions or a combination. Proposed SEC SPAC rules could increase transaction costs and timing burdens.
- Disclosure controls were judged effective as of September 30, 2022; no material change in internal control over financial reporting was reported. The company reported no material legal proceedings outside the ordinary course.
Most important facts to verify
- Confirm the intended company: this filing names Anzu Special Acquisition Corp I, not Envoy Medical, Inc.
- Verify any business-combination or extension developments after September 30, 2022, given the March 4, 2023 deadline stated in the filing.
- Reconcile the reported cash: the balance sheet shows $301,997, while MD&A says $476,948 was held outside the trust account and available for working capital.
- Check the stated effective tax rates against the reported tax provisions and pretax income; the filing’s percentages do not appear to reconcile clearly with those amounts.
- Confirm the sponsor loan balance, repayment terms, and any additional financing availability, as well as the remaining deferred underwriting fees and any other waived amounts.